Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 4/20 | 0.63 |
| ▸ | KDM1A | O60341 | 1/20 | 0.56 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.52 |
| ▸ | PDE4A | P27815 | 2/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.52 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.48 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.48 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.48 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.48 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.48 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.48 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.48 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.48 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3111017 | 0.93 | RBP4 (0.57) | RBP4KDM1AGPR119PDE4BPDE4A | |
| SCHEMBL71246 | 0.90 | EPHX2 (0.56) | RBP4KDM1AGPR119KDM4E | |
| SCHEMBL3100314 | 0.86 | GPR119 (0.52) | RBP4KDM1AGPR119PDE4BPDE4A | |
| SCHEMBL8095094 | 0.86 | GPR119 (0.53) | RBP4KDM1AGPR119PDE4BPDE4A | |
| SCHEMBL19839235 | 0.86 | PDE4B (0.64) | KDM1AGPR119PDE4BPDE4APDE4C | |
| SCHEMBL21765007 | 0.86 | KDM1A (0.57) | KDM1AGPR119PDE4BPDE4APDE4C | |
| SCHEMBL74564 | 0.86 | KDM1A (0.57) | KDM1AGPR119PDE4BPDE4APDE4C | |
| SCHEMBL3094603 | 0.85 | GPR119 (0.58) | RBP4KDM1AGPR119PDE4BPDE4A | |
| SCHEMBL17955461 | 0.85 | RBP4 (0.67) | RBP4CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL3096195 | 0.85 | RBP4 (0.67) | RBP4KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2202223-B1 | HETEROCYCLIC COMPOUND AS BLOOD RBP4 LOWERING AGENT | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-25 | — | — | EP | disclosed |
| EP-2202223-B1 | HETEROCYCLIC COMPOUND AS BLOOD RBP4 LOWERING AGENT | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-25 | — | — | EP | disclosed |
| US-9487509-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487509-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| US-9487509-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-11-08 | — | — | US | disclosed |
| US-20140066420-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-06 | — | — | US | disclosed |
| US-20140066420-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-06 | — | — | US | disclosed |
| US-20140066420-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-06 | — | — | US | disclosed |
| US-8586571-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | disclosed |
| US-8586571-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-11-19 | — | — | US | disclosed |
| US-20100292206-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| US-20100292206-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-18 | — | — | US | disclosed |
| EP-2202223-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-06-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066420-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RAVER1 | RBP4 1/4885KDM1A 868/4885GPR119 743/4885 |
| US-20100292206-A1 | HETEROCYCLIC COMPOUND | RBP4, RBP1, RAVER1 | RBP4 1/4885KDM1A 868/4885GPR119 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.